Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

ProQR Therapeutics (PRQR) Enterprise Value (2016 - 2025)

ProQR Therapeutics' Enterprise Value history spans 6 years, with the latest figure at -$107.6 million for Q4 2025.

  • On a quarterly basis, Enterprise Value rose 32.62% to -$107.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$107.6 million, a 32.62% increase, with the full-year FY2025 number at -$107.6 million, up 32.62% from a year prior.
  • Enterprise Value hit -$107.6 million in Q4 2025 for ProQR Therapeutics, up from -$159.7 million in the prior quarter.
  • Over the last five years, Enterprise Value for PRQR hit a ceiling of -$91.5 million in Q1 2021 and a floor of -$219.1 million in Q4 2021.
  • Historically, Enterprise Value has averaged -$138.8 million across 5 years, with a median of -$136.0 million in 2023.
  • Biggest five-year swings in Enterprise Value: tumbled 139.65% in 2021 and later surged 55.28% in 2022.
  • Tracing PRQR's Enterprise Value over 5 years: stood at -$219.1 million in 2021, then surged by 55.28% to -$98.0 million in 2022, then crashed by 30.59% to -$128.0 million in 2023, then dropped by 24.77% to -$159.7 million in 2024, then soared by 32.62% to -$107.6 million in 2025.
  • Business Quant data shows Enterprise Value for PRQR at -$107.6 million in Q4 2025, -$159.7 million in Q4 2024, and -$128.0 million in Q4 2023.